.Nature Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after an average follow-up of 11 months, patients along with metastatic gastrointestinal lumps who obtained biomarker-matched treatments based upon distributing tumor DNA profiling revealed a greater clinical benefit than those getting incomparable therapy.